P
At PMV, we believe that by specifically targeting each mutant p53 we can fundamentally disrupt the course of cancer. Our research and development efforts are dedicated to selectively targeting mutant p53, providing unique therapies for any patient whose tumor harbors these gene mutations.
Investor insights
Funding rounds participated in
$70M sweet spot round size
Investor type
Public Company
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
2013
Funding rounds raised
Total raised
$70M
from investors over 1 rounds
P
PMV Pharmaceuticals, Inc. raised $70M on September 3, 2020